ストックスクリーナーアプリを入手
68.11
2.92%
1.93
Rhythm Pharmaceuticals Inc (RYTM) 最新ニュース
Jefferies Maintains Buy Rating on Rhythm Pharmaceuticals (RYTM), Sets $80 Price Target - Insider Monkey
Rhythm Pharmaceuticals at Jefferies Conference: Strategic Pipeline Insights By Investing.com - Investing.com Canada
Rhythm Pharmaceuticals at Jefferies Conference: Strategic Pipeline Insights - Investing.com
(RYTM) Proactive Strategies - news.stocktradersdaily.com
Rhythm Pharmaceuticals (RYTM) Gets Price Target Upgrade by Stifel Amid Obesity Drug Optimism - Insider Monkey
Stifel Nicolaus Issues Positive Forecast for Rhythm Pharmaceuticals (NASDAQ:RYTM) Stock Price - Defense World
Rhythm Pharmaceuticals (RYTM) Target Price Raised by Stifel Anal - GuruFocus
12 Analysts Assess Rhythm Pharmaceuticals: What You Need To Know - Benzinga
Rhythm Pharmaceuticals (RYTM) Stock Jumps Nearly 6%: What's Driving the Upbeat Tempo? - Daily Chhattisgarh News
Stifel raises Rhythm Pharma stock target to $94, keeps Buy rating - Investing.com Canada
Rhythm Pharmaceuticals (RYTM) Target Price Boosted by Analyst | - GuruFocus
Rhythm Pharmaceuticals (RYTM) Target Price Boosted by Analyst | RYTM Stock News - GuruFocus
Ameriprise Financial Inc. Purchases 11,480 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - Defense World
POMC Deficiency Obesity Market on Track for Major Expansion - openPR.com
(RYTM) Investment Analysis - news.stocktradersdaily.com
Deutsche Bank AG Has $2.73 Million Position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - Defense World
Gotham Asset Management LLC Sells 2,685 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - Defense World
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Receives $75.38 Consensus Price Target from Analysts - Defense World
Rhythm Pharmaceuticals Announces New Data Presentations on Patie - GuruFocus
(RYTM) On The My Stocks Page - news.stocktradersdaily.com
RYTM Shows Positive Results in Hypothalamic Obesity Treatment | - GuruFocus
RYTM Shows Positive Results in Hypothalamic Obesity Treatment | RYTM Stock News - GuruFocus
Rhythm Pharmaceuticals Announces New Data Presentations on Patients with Acquired or Congenital Hypothalamic Obesity (N=35) Treated with Setmelanotide for up to Nine Months in French Early-access Program - GlobeNewswire
New Clinical Data: Rhythm's Obesity Drug Achieves 23% Weight Loss in Real-World Study, FDA Filing Coming Q3 - Stock Titan
Raymond James Financial Inc. Buys New Shares in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - Defense World
Rhythm pharmaceuticals outlines Q3 2025 filing for acquired hypothalamic obesity treatment - MSN
HC Wainwright Has Negative Estimate for RYTM Q2 Earnings - Defense World
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Q1 2025 Earnings Call Transcript - Insider Monkey
Rhythm Pharmaceuticals (NASDAQ:RYTM) Trading Down 6.6% on Disappointing Earnings - Defense World
Needham & Company LLC Increases Rhythm Pharmaceuticals (NASDAQ:RYTM) Price Target to $72.00 - Defense World
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q1 Loss, Lags Revenue Estimates - MSN
Rhythm Pharmaceuticals Inc (RYTM) Q1 2025 Earnings Call Highlights: Strong IMCIVREE Sales and ... - Yahoo Finance
Rhythm Pharmaceuticals Q1 2025 slides: Revenue grows 45% as HO program advances - Investing.com Canada
RHYTHM PHARMACEUTICALS, INC. SEC 10-Q Report - TradingView
Rhythm Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (15 Ratings) - Benzinga
Rhythm Pharmaceuticals (RYTM) Price Target Raised by Needham | RYTM Stock News - GuruFocus
Rhythm Pharmaceuticals Q1 2025 Earnings Call Transcript - MarketBeat
Earnings call transcript: Rhythm Pharmaceuticals misses Q1 2025 EPS estimates - Investing.com
Rhythm Pharmaceuticals' Q1 Net Loss Narrows, Revenue Increases - marketscreener.com
RYTM Misses Q1 Revenue Estimates, Focuses on Future Therapies for Hypothalamic Obesity | RYTM Stock News - GuruFocus
Rhythm Pharmaceuticals Reports Q1 2025 Earnings: EPS of ($0.81) Misses Estimate, Revenue of $37.7 Million Below Expectations - GuruFocus
Rhythm Pharmaceuticals Reports First Quarter 2025 Financial Results and Business Update - The Manila Times
Earnings Flash (RYTM) Rhythm Pharmaceuticals Posts Q1 Loss $0.81, vs. FactSet Est of $0.73 Loss - marketscreener.com
BRIEF-Rhythm Pharmaceuticals Q1 Net Income USD -49.498 Million - TradingView
Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences - The Manila Times
Rare Disease Leader Rhythm Pharmaceuticals Lines Up Triple Conference Appearances in Healthcare Circuit - Stock Titan
Mariner LLC Invests $254,000 in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - Defense World
Rhythm Pharmaceuticals (RYTM) Expected to Announce Earnings on Wednesday - Defense World
Rhythm Pharmaceuticals, Inc.'s (NASDAQ:RYTM) Shares Climb 36% But Its Business Is Yet to Catch Up - simplywall.st
(RYTM) Trading Report - news.stocktradersdaily.com
BlackRock, Inc. Reduces Stake in Rhythm Pharmaceuticals Inc - GuruFocus
Will Rhythm Pharmaceuticals, Inc. (RYTM) Report Negative Earnings Next Week? What You Should Know - Yahoo Finance
1.21%
1.51%
大文字化:
|
ボリューム (24 時間):